Vertex Pharmaceuticals bets on kidney disease treatment with $4.9 billion Alpine Immune deal
CNBCVertex Pharmaceuticals will buy Alpine Immune Sciences for about $4.9 billion in cash, gaining access to a treatment for an autoimmune disease of the kidney.